Equities analysts predict that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will report $5.43 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Dova Pharmaceuticals’ earnings, with estimates ranging from $4.00 million to $7.42 million. Dova Pharmaceuticals reported sales of $4.58 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.6%. The company is expected to issue its next earnings report on Thursday, August 8th.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year sales of $30.14 million for the current year, with estimates ranging from $27.00 million to $33.90 million. For the next financial year, analysts forecast that the company will report sales of $90.02 million, with estimates ranging from $55.37 million to $120.31 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.10. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. The business had revenue of $4.00 million for the quarter, compared to the consensus estimate of $3.46 million.
In other Dova Pharmaceuticals news, Director Paul B. Manning bought 68,000 shares of the business’s stock in a transaction dated Thursday, March 7th. The shares were purchased at an average price of $7.48 per share, with a total value of $508,640.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 60.30% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Morgan Stanley grew its stake in shares of Dova Pharmaceuticals by 688.2% during the first quarter. Morgan Stanley now owns 161,237 shares of the company’s stock valued at $1,434,000 after buying an additional 140,781 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Dova Pharmaceuticals during the first quarter valued at approximately $229,000. State of Wisconsin Investment Board grew its stake in shares of Dova Pharmaceuticals by 29.3% during the first quarter. State of Wisconsin Investment Board now owns 15,900 shares of the company’s stock valued at $141,000 after buying an additional 3,600 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Dova Pharmaceuticals by 22.0% during the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock valued at $336,000 after buying an additional 2,400 shares during the last quarter. Finally, BlackRock Inc. grew its stake in shares of Dova Pharmaceuticals by 0.4% during the first quarter. BlackRock Inc. now owns 1,156,052 shares of the company’s stock valued at $10,277,000 after buying an additional 4,217 shares during the last quarter. 31.17% of the stock is currently owned by hedge funds and other institutional investors.
DOVA stock traded down $0.85 during midday trading on Monday, reaching $10.68. 11,050 shares of the company traded hands, compared to its average volume of 165,356. Dova Pharmaceuticals has a 52-week low of $5.62 and a 52-week high of $35.33. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.46 and a quick ratio of 4.27. The company has a market cap of $315.36 million, a PE ratio of -4.17 and a beta of 2.06.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.
Read More: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.